Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiac Arrhythmia and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CALM3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CALM3 Wild-Type & Mutant (N98S, D130G, F142L) Recombinant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CALM3 Products |
| Gene Delivery | CALM3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View CALM3 Products |
| Benchmark Ab | Anti-CALM3 Recombinant Antibody Sequence-verified positive control for Western Blot and ELISA development. |
View CALM3 Products |
| Validator | CALM3 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View CALM3 Products |
| Related Target A | RYR2 (Ryanodine Receptor 2) Primary physiological partner; CALM3 mutations disrupt RYR2 regulation, driving CPVT. |
View RYR2 Products |
| Related Target B | CaMKII (CAMK2A) Downstream effector kinase activated by Ca2+/Calmodulin complex, key therapeutic target. |
View CAMK2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-Dependent Conformational State (Apo vs. Holo) | High-purity recombinant CALM3 proteins verified for calcium-binding integrity via theoretical MW and MS analysis. |
| Arrhythmia-Associated Mutant Screening | Specific point-mutation proteins (N98S, D130G, F142L) available to evaluate mutant-specific drug rescue. |
| Lack of Controls | Sequence-verified biosimilar recombinant antibodies included |
| False Positives | Sequence-validated siRNA sets included for target knockdown verification |
Live Calmodulin/CALM3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Calmodulin (CALM3) modulators is intensifying, with major players shifting focus from traditional non-selective antagonists to isoform-specific and mutation-targeted therapeutics. CALM3 is one of three genes (CALM1, CALM2, CALM3) encoding the identical 149-amino-acid Calmodulin protein. Mutations in CALM3 are directly linked to severe, life-threatening cardiac channelopathies, including Long QT Syndrome (LQTS) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). As first-generation systemic calmodulin inhibitors proved limited by off-target toxicities, the next wave of R&D is targeting downstream effectors (like CaMKII) or employing gene-therapy approaches to selectively knock down mutant CALM3 alleles while preserving wild-type expression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (siRNA/AAV) | Academic Consortia, Biotech Startups | CALM3-related LQTS / CPVT | Allele-specific knockdown validation (Need mutant/WT sequence-verified targets) |
| Small Molecule Modulators | Pharmaceutical Developers | Oncology (KRAS-driven), Arrhythmias | Calcium-dependent binding assays (Need high-purity Apo/Holo recombinant proteins) |
| Peptide Inhibitors | Translational Research Labs | Inflammatory Diseases, Neurodegeneration | Target interaction assays (Need stable, sequence-verified CALM3 proteins) |